newsfilter
← Latest News
Business Wire·

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Successfully Reduced-to-Practice Critical Aspect of Commercial-Scale, Cell-Based, GMP